title: Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.
authors.affiliation: Geisel School of Medicine at Dartmouth, Lebanon, NH.
authors.forename: Nicole C
authors.initials: NC
authors.lastname: Smits
authors.affiliation: Geisel School of Medicine at Dartmouth, Lebanon, NH charles.l.sentman@dartmouth.edu.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Sentman
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000187:drug effects / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017252:CD3 Complex / Q000187:drug effects / Q000276:immunology; D004334:Drug Administration Schedule; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007262:Infusions, Intravenous; D008213:Lymphocyte Activation / Q000187:drug effects*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000276:immunology*; D020714:Maximum Tolerated Dose; D058990:Molecular Targeted Therapy / Q000379:methods*; D009422:Nervous System Diseases / Q000139:chemically induced; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000970:Antineoplastic Agents; D017252:CD3 Complex; C510808:blinatumomab